990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
| Autor: | Perets, R., Stemmer, S.M., Geva, R., Golan, T., Fakih, M., Cohen, J.E., Lieu, C., Jin, Z., Lorusso, P., Friedman, I., Hakim, M., Haves Ziv, D., Hashmueli, S., Mandel, I., Ben Moshe, T., Crawford, N., Abbadessa, G., Perez, R., Wu, M., Borad, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S675-S675 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|